PBD Biotech developers of Actiphage TB has announced it has secured the grant of a US patent for its diagnostic kit. The company is exhibiting in the AACC Clinical Lab Expo on booth #4578.
Grant of this US patent relating to Mycobacteria detection using bacteriophages, and specifically to the diagnostic kit, provides further important protection for the Actiphage technology.
PBD Biotech is a clinical-stage diagnostic company and pioneer in phage-based diagnostics. It is focused on the development of Actiphage TB as a blood test for the detection of tuberculosis in latent TB screening and drug management.
PBD Biotech recently initiated one of the largest clinical trials for Actiphage TB to date, building on a prior study that demonstrated detection of Mycobacteria tuberculosis (Mtb) in the blood of naive pulmonary TB patients.
PBD Biotech is one of eight start-ups selected to present at the DxPx Conference US 2023, part of the AACC Clinical Lab Expo in Anaheim, California on July 26 2023.
PBD Biotech is exhibiting in the AACC Clinical Lab Expo on Booth #4578.
